Flick of the switch

Researchers from The Rockefeller University have developed an antibody-engineering technique that increases the antitumor potency of an agonistic anti-CD40 mAb.¹ The method involves switching

Fc g-receptor IIb, an antibody co-receptor that binds to the invariant region of antibodies, from an inhibitor to a promoter of immune cell activation...